Evidence map›Paper›PMID 41834466›Full record

ArticleAngewandte Chemie (International ed. in English)2026

NiH-Catalyzed Enantioconvergent α-Alkenylation of Carbonyl Compounds via Markovnikov Alkyne Hydronickellation.

Hyeontaek Nam, Seji Jang, Dongwook Kim, Sangwon Seo

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hyeontaek NamDepartment of Physics and Chemistry, DGIST, Daegu, Republic of Korea.
Seji JangDepartment of Physics and Chemistry, DGIST, Daegu, Republic of Korea.
Dongwook KimCenter For Catalytic Hydrocarbon Functionalizations, Institute For Basic Science (IBS), Daejeon, Republic of Korea.
Sangwon SeoDepartment of Physics and Chemistry, DGIST, Daegu, Republic of Korea.ORCID https://orcid.org/0000-0003-2281-9167

Funding

DGIST 2023040012National Research Foundation of Korea RS-2024-00454580National Research Foundation of Korea RS-2025-00518096
6 · The paper itself

Abstract

β-Methylene carbonyl motifs constitute privileged structural frameworks that play vital roles as a pharmacophore and serve as key intermediates in the assembly of architecturally complex molecules. Despite their synthetic importance, asymmetric approaches for their preparation remain scarce and are largely confined to substrate-controlled or stoichiometric chiral auxiliary methods. Herein, we report a nickel hydride-catalyzed enantioconvergent α-alkenylation of carbonyl compounds with alkynes, providing a direct and general route to α-chiral β-methylene carbonyl derivatives. The transformation proceeds via Markovnikov-selective alkyne hydronickellation followed by nickel-radical recombination to forge the α-stereogenic center, delivering the desired products with high levels of regio- and enantioselectivity. The protocol accommodates a wide range of alkynes and α-halocarbonyl partners, displays excellent functional group tolerance, and can be applied to the modification of biologically relevant molecules. Mechanistic investigations indicate that a partially protic Ni(II)H species governs the observed regioselectivity, while enantio-discrimination occurs during the radical capture step. This work establishes NiH catalysis as a versatile platform for expanding the synthetic repertoire for enantioenriched β-methylene carbonyl architectures.

Indexed as

alkenylationalkynesasymmetric catalysisnickelreaction mechanisms

Identifiers

PMID41834466
PMCPMC13098307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.